Homologous recombination and DNA repair are important for genome maintenance.
Genetic variations in essential homologous recombination genes, including BRCA1 and …

In recent years, synthetic lethality has been recognized as a solid paradigm for anticancer
therapies. The discovery of a growing number of synthetic lethal targets has led to a …

The effective potency and resistance of poly (ADP-ribose) polymerase (PARP) inhibitors limit
their application. Here, we exploit a new paradigm that mimics the effects of breast cancer …

Targeting DNA repair proteins with small-molecule inhibitors became a proven anti-cancer
strategy. Previously, we identified an inhibitor of a major protein of homologous …

The vast majority of cancer patients receive DNA-damaging drugs or ionizing radiation (IR)
during their course of treatment, yet the efficacy of these therapies is tempered by DNA …

Platinum drugs are heavily used first‐line chemotherapeutic agents for many solid tumours
and have stimulated substantial interest in the biological activity of DNA‐binding metal …

Synergistic drug combinations can extend the use of poly (ADP-ribose) polymerase
inhibitors (PARPi) such as Olaparib to BRCA-proficient tumors and overcome acquired or de …

Synthetic lethality is an innovative framework for discovering novel anticancer drug
candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with …

BRCA2 controls RAD51 recombinase during homologous DNA recombination (HDR)
through eight evolutionarily conserved BRC repeats, which individually engage RAD51 via …

RAD51 is an ATP-dependent recombinase, recruited by BRCA2 to mediate DNA double-
strand breaks repair through homologous recombination and represents an attractive cancer …